Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: Implications for the future

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 9, Issue 5, 2009, Pages 475-484

  Godman, Brian ^a,b,c   Burkhardt, Thomas ^d   Bucsics, Anna ^d   Wettermark, Björn ^a,e   Wieninger, Peter ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d Hauptverband der Österreichischen Sozialversicherungsträger ^*  (Austria)

^e STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

Drug cost; Generic; Proton pump inhibitor; Reference pricing; Reform; Statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; ESOMEPRAZOLE; FLUINDOSTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; MEVINOLIN; OMEPRAZOLE; PANTOPRAZOLE; PRAVASTATIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; ROSUVASTATIN; SIMVASTATIN;

AMBULATORY CARE; ARTICLE; AUSTRIA; DRUG COST; DRUG UTILIZATION; ECONOMICS; EDUCATION; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; ISCHEMIC HEART DISEASE; PRESCRIPTION;

AMBULATORY CARE; AUSTRIA; DRUG COSTS; DRUGS, GENERIC; HEALTH CARE REFORM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NATIONAL HEALTH PROGRAMS; PHYSICIAN'S PRACTICE PATTERNS; PROTON PUMP INHIBITORS;

EID: 70449659593     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.09.43     Document Type: Article

References (26)

1. Godman B, Bucsics A, Burkhardt T, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomics Outcomes Res. 8(4), 357-371 (2008).
2. Wettermark B, Godman B, Andersson K, Gustafsson LL et al. Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. Pharmacoeconomics 26(7), 537-550 (2008). (Pubitemid 351871549)
3. Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26(2), 91-98 (2008).
4. Godman B, Wettermark B, Hoffman M, Andersson K, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev. Pharmacoeconomcis Outcomes Res. 9(1), 65-83 (2009).
5. Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics 27(5), 435-438 (2009).
6. Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the rational use of new medicines across European healthcare systems - a position paper. Eur. J. Clin. Pharmacol. 64, 1137-1138 (2008).
7. Walley T, Folino-Gallo P, Schwabe U, van Ganse E; EuroMedStat group. Variations and increase use of statins across Europe: data from administrative databases. BMJ 328, 385-386 (2004). (Pubitemid 38241189)
8. Winkelmayer C, Asslaber M, Brookhart M et al. Impact of reimbursed changes on statin use among patients with diabetes in Austria. Basic Clin. Pharm. Toxicol. 105(Suppl. 1), 25 (2009).
9. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking - an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7(3), 1-11 (2009).
10. Godman B, Vlahovic-Palcevski V, Laius O et al. Trends in consumption and expenditure of proton pump inhibitors (PPIs) in 20 European countries. Basic Clin. Pharm. Toxicol. 105(Suppl. 1), 37 (2009).
11. Godman B, Wettermark B, Vlahovic-Palcevski V et al. Impact of reforms to enhance the quality and efficiency of statin prescribing across 20 European countries. Basic Clin. Pharm. Toxicol. 105(Suppl. 1), 35 (2009).
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
13. Collins R, Armitage J, Parish S et al. MRC/ BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361, 2005-2016 (2003).
14. Rydén L, Standl E, Bartnik M et al.; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur. Heart J. 28(1), 88-136 (2007). (Pubitemid 46137814)
15. Sakshaug S, Furu K, Karlstead O et al. Switching statins in Norway after new reimbursement policy - a nationwide prescription study Br. J. Clin. Pharm. 64(4), 476-481 (2007). (Pubitemid 47404299)
16. Winkelmayer WC, Bucsics AE, Schautzer A, Wieninger P, Pogantsch M; Pharmacoeconomics Advisory Council of the Austrian Sickness Funds. Use of recommended medications after myocardial infarction in Austria. Eur. J. Epidemiol. 23(2), 153-162 (2008).
17. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 336, 2-3 (2008).
18. Björnsson E, Abrahamsson H, Simrén M et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment. Pharmacol Ther 24(6), 945-954 (2006).
19. Beishon J, McBride T. Scharaschkin S et al. National Audit Office. Prescribing costs in primary care. 14 May 2007 www.nao.org.uk (Accessed 21 May 2008)
20. Simoens S, De Coster S. Sustaining Generic Markets in Europe. Katholieke Universiteit Leuven, Research Centre for Pharmaceutical Care and Pharmaco-economics, Leuven, Belgium (2006) www.egagenerics.com/doc/ simoensreport-2006-2004.pdf (Accessed 16 October 2008)
21. [Medicines and Reason Initiatives] (in German) www.sozialversicherung.at/ arzneiundvernunft (Accessed 3 May 2009)
22. Tomas Dolezal. The Czech Republic www.ceestahc.org/pliki/symp2008/ dolezal.pdf (Accessed 6 January 2009)
23. WHO. Guidelines for ATC Classification and DDD Assignment. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway (2009) www.whocc.no (Accessed 6 January 2009)
24. WHO. Introduction to Drug Utilisation Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization, Research and Clinical Pharmacological Services. ISBN 92 4 156234 X (NLM classification: WB 330) www.who.int/medicines/areas/quality-safety/safety-efficacy/Drug%20 utilization%20research.pdf (Accessed 30 April 2009)
25. Eriksson G, Lundin D. The Review of Medicines for Treating Lipid Disorders; a Summary. TLV, Sweden (2009) www.tlv.se/Upload/Genomgangen/ summary-lipids.pdf (Accessed 30 March 2009)
26. Wessling A, Lundin D. The Review of Drugs Against Disease Caused by Acid Stomach - A Summary. Pharmaceuticals Benefits Board, Solna, Sweden (2006) www.tlv.se/Upload/Genomgangen/ summary-stommach-acid.pdf (Accessed 6 January 2009)